Movymia (Teriparatide)

Teriparatide, the active ingredient in Movymia, is a parathyroid hormone analog presented as a subcutaneous injection for subcutaneous use. It treats osteoporosis in postmenopausal women and men at high risk of fracture. GNH USA supplies Movymia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movymia (teriparatide) acts on the skeletal remodeling pathway to treat osteoporosis.

- Osteoporosis in postmenopausal women: reduces the risk of vertebral and non‑vertebral fractures by increasing bone density. - Osteoporosis in men at high risk of fracture: improves bone mass and lowers fracture incidence. - Severe osteoporosis: stimulates new bone formation to increase overall bone strength.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Dizziness: transient light‑headedness, especially after injection. - Leg cramps: muscle tightness in the lower limbs. - Injection site reactions: redness, swelling, or pain at the administration site. - Hypercalcemia: elevated blood calcium levels, often mild.

Serious or Rare Side Effects: - Osteosarcoma: extremely rare malignant bone tumor. - Severe hypercalcemia: marked elevation of calcium requiring medical intervention. - Anaphylactic reactions: acute allergic response with breathing difficulty. - Hypotension: significant drop in blood pressure post‑injection. - Persistent bone pain: prolonged discomfort beyond typical injection site pain.

Before initiating therapy, evaluate calcium status and assess for contraindications.

- Calcium monitoring: regularly check serum calcium levels during treatment. - Hypercalcemia risk: avoid concurrent high‑dose calcium or vitamin D supplements. - Bone cancer history: do not use in patients with prior osteosarcoma or unexplained bone lesions. - Specialist supervision: treatment should be overseen by a physician experienced in metabolic bone disease. - Contraindication in Paget disease: avoid use in patients with active Paget disease of bone. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Teriparatide may interact with agents that affect calcium balance.

Major Interactions (Avoid): - High‑dose vitamin D supplements: can exacerbate hypercalcemia. - Calcium carbonate or other calcium salts: increase risk of elevated serum calcium. - Thiazide diuretics: may potentiate calcium retention.

Moderate Interactions (Monitor Closely): - Bisphosphonates: concurrent use may blunt teriparatide’s anabolic effect. - Corticosteroids: may reduce bone‑building response, requiring close monitoring. - Loop diuretics: can affect calcium excretion, necessitating periodic calcium checks.